Buflomedil

Title: Buflomedil
CAS Registry Number: 55837-25-7
CAS Name: 4-(1-Pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone
Additional Names: 2¢,4¢,6¢-trimethoxy-4-(1-pyrrolidinyl)butyrophenone; (2,4,6-trimethoxyphenyl)-(3-pyrrolidinopropyl) ketone
Molecular Formula: C17H25NO4
Molecular Weight: 307.38
Percent Composition: C 66.43%, H 8.20%, N 4.56%, O 20.82%
Literature References: Prepn: L. Lafon, DE 2122144; idem, US 3895030 (both 1971 to Orsymonde). Pharmacology: J. Duteil et al., Therapie 30, 207 (1975); C. Debray et al., ibid. 259. HPLC determn: J. A. Badmin et al., J. Chromatogr. 172, 319 (1979). Clinical pharmacokinetics: U. Gundert-Remy et al., Eur. J. Clin. Pharmacol. 20, 459 (1981). Comparative safety and efficacy study: G. Rosas et al., Angiology 32, 291 (1981). Review of pharmacology and therapeutic effects: S. P. Clissold et al., Drugs 33, 430-460 (1987).
Derivative Type: Hydrochloride
CAS Registry Number: 35543-24-9
Manufacturers' Codes: LL-1656
Trademarks: Bufedil (Abbott); Buflan (Fournier); Buflocit (CT); Buflonat (Nattermann); Fonzylane (Orsymonde); Irrodan (Biomed. Foscama); Lofton (Abbott); Loftyl (Abbott); Provas (Sanol Schwarz)
Molecular Formula: C17H25NO4.HCl
Molecular Weight: 343.85
Percent Composition: C 59.38%, H 7.62%, N 4.07%, O 18.61%, Cl 10.31%
Properties: White crystals from isopropanol, mp 192-193°. LD50 in mice (mg/kg): 80 ±4.6 i.v. (Lafon).
Melting point: mp 192-193°
Toxicity data: LD50 in mice (mg/kg): 80 ±4.6 i.v. (Lafon)
Therap-Cat: Vasodilator (peripheral).
Keywords: Vasodilator (Peripheral).
Bufogenin B Buformin Bufotalin Bufotenine Bufotoxin

Buflomedil
Buflomedil.svg
Identifiers
CAS number 55837-25-7 YesY
PubChem 2467
ChemSpider 2373 YesY
ChEMBL CHEMBL188921 YesY
ATC code C04AX20
Jmol-3D images Image 1
Properties
Molecular formula C17H25NO4
Molar mass 307.38 g/mol
 YesY (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl